Cargando…
Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades
BACKGROUND: Despite using renin–angiotensin system (RAS) blockades, some of the patients with immunoglobulin A (IgA) nephropathy often had persistent proteinuria of more than 500 mg/d. They need to be managed further by alternative methods to halt the progression of the disease; these methods could...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716093/ https://www.ncbi.nlm.nih.gov/pubmed/26894022 http://dx.doi.org/10.1016/j.krcp.2012.06.006 |
_version_ | 1782410498494431232 |
---|---|
author | Yang, Byeong Yun Lee, Hee Seon Song, Sang Heon Kwak, Ihm Soo Lee, Soo Bong Lee, Dong Won Seong, Eun Young |
author_facet | Yang, Byeong Yun Lee, Hee Seon Song, Sang Heon Kwak, Ihm Soo Lee, Soo Bong Lee, Dong Won Seong, Eun Young |
author_sort | Yang, Byeong Yun |
collection | PubMed |
description | BACKGROUND: Despite using renin–angiotensin system (RAS) blockades, some of the patients with immunoglobulin A (IgA) nephropathy often had persistent proteinuria of more than 500 mg/d. They need to be managed further by alternative methods to halt the progression of the disease; these methods could also be applied safely over a long period of time. In this context, sulodexide has been studied for the management of diabetic nephropathy. METHODS: A retrospective review was carried out involving 20 patients with IgA nephropathy who had been taking sulodexide (50 mg daily) as an add-on therapy together with an optimal dose of RAS blockades during 2008–2009. We evaluated the proteinuria reduction rates and renal function changes. RESULTS: During 11.1±72.7 months of follow-up duration, urinary protein-to-creatinine ratio (UPCR) decreased for 1.57±0.6 to 1.17±0.7 g/g (P=0.032). Twenty-five percent of the patients showed a greater than 50% reduction of UPCR, and 40% had a UPCR of less than 1.0 g/g at their final observations. The analysis of the factors contributing to the effect found that a higher pretreatment UPCR showed a significant correlation with the UPCR decrease (r=0.45, P=0.047). Neither the adverse effects nor the renal function impairments were documented during the management. CONCLUSION: Low-dose sulodexide has an additional modest antiproteinuric effect on IgA nephropathy undergoing RAS blockade therapy. |
format | Online Article Text |
id | pubmed-4716093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-47160932016-02-18 Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades Yang, Byeong Yun Lee, Hee Seon Song, Sang Heon Kwak, Ihm Soo Lee, Soo Bong Lee, Dong Won Seong, Eun Young Kidney Res Clin Pract Original Article BACKGROUND: Despite using renin–angiotensin system (RAS) blockades, some of the patients with immunoglobulin A (IgA) nephropathy often had persistent proteinuria of more than 500 mg/d. They need to be managed further by alternative methods to halt the progression of the disease; these methods could also be applied safely over a long period of time. In this context, sulodexide has been studied for the management of diabetic nephropathy. METHODS: A retrospective review was carried out involving 20 patients with IgA nephropathy who had been taking sulodexide (50 mg daily) as an add-on therapy together with an optimal dose of RAS blockades during 2008–2009. We evaluated the proteinuria reduction rates and renal function changes. RESULTS: During 11.1±72.7 months of follow-up duration, urinary protein-to-creatinine ratio (UPCR) decreased for 1.57±0.6 to 1.17±0.7 g/g (P=0.032). Twenty-five percent of the patients showed a greater than 50% reduction of UPCR, and 40% had a UPCR of less than 1.0 g/g at their final observations. The analysis of the factors contributing to the effect found that a higher pretreatment UPCR showed a significant correlation with the UPCR decrease (r=0.45, P=0.047). Neither the adverse effects nor the renal function impairments were documented during the management. CONCLUSION: Low-dose sulodexide has an additional modest antiproteinuric effect on IgA nephropathy undergoing RAS blockade therapy. Elsevier 2012-09 2012-06-27 /pmc/articles/PMC4716093/ /pubmed/26894022 http://dx.doi.org/10.1016/j.krcp.2012.06.006 Text en © 2012. The Korean Society of Nephrology. Published by Elsevier. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Yang, Byeong Yun Lee, Hee Seon Song, Sang Heon Kwak, Ihm Soo Lee, Soo Bong Lee, Dong Won Seong, Eun Young Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades |
title | Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades |
title_full | Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades |
title_fullStr | Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades |
title_full_unstemmed | Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades |
title_short | Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades |
title_sort | use of low-dose sulodexide in iga nephropathy patients on renin–angiotensin system blockades |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716093/ https://www.ncbi.nlm.nih.gov/pubmed/26894022 http://dx.doi.org/10.1016/j.krcp.2012.06.006 |
work_keys_str_mv | AT yangbyeongyun useoflowdosesulodexideiniganephropathypatientsonreninangiotensinsystemblockades AT leeheeseon useoflowdosesulodexideiniganephropathypatientsonreninangiotensinsystemblockades AT songsangheon useoflowdosesulodexideiniganephropathypatientsonreninangiotensinsystemblockades AT kwakihmsoo useoflowdosesulodexideiniganephropathypatientsonreninangiotensinsystemblockades AT leesoobong useoflowdosesulodexideiniganephropathypatientsonreninangiotensinsystemblockades AT leedongwon useoflowdosesulodexideiniganephropathypatientsonreninangiotensinsystemblockades AT seongeunyoung useoflowdosesulodexideiniganephropathypatientsonreninangiotensinsystemblockades |